58256-10-3 Usage
General Description
5-(1-Naphthyl)thiophene-2-carboxylic acid is a chemical compound that consists of a thiophene ring with a naphthyl group attached to the 5th position and a carboxylic acid functional group attached to the 2nd position. It is used in various research and industrial applications, including as a building block for the synthesis of organic compounds and pharmaceuticals. The compound has also been studied for its potential anti-cancer and anti-inflammatory properties. Its molecular structure and properties make it a versatile and valuable chemical for use in organic synthesis and drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 58256-10-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,8,2,5 and 6 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 58256-10:
(7*5)+(6*8)+(5*2)+(4*5)+(3*6)+(2*1)+(1*0)=133
133 % 10 = 3
So 58256-10-3 is a valid CAS Registry Number.
InChI:InChI=1/C15H10O2S/c16-15(17)14-9-8-13(18-14)12-7-3-5-10-4-1-2-6-11(10)12/h1-9H,(H,16,17)
58256-10-3Relevant articles and documents
INHIBITORS FOR HDAC8
-
Page/Page column 83; sheet 9/9, (2008/12/08)
INHIBITORS FOR HDAC8 ABSTRACT OF THE DISCLOSURE This invention discloses a new HDAC inhibitor scaffold designed to exploit a unique sub-pocket of the HDAC8 active site. These compounds are based on inspection of HDAC8 crystal structures bound to various inhibitors, which showed that the HDAC8 active site is surprisingly malleable and can accommodate inhibitor structures that are distinct from the canonical "zinc-binding group-linker-cap group" structures of SAHA, TSA and similar HDAC inhibitors. Some of the new inhibitors based on this new scaffold are >100 fold selective for HDAC8 over other class I and class II HDACs with IC50 values 1μM against HDAC8. The present invention provides a new type of "linkerless" HDAC8 inhibitors and methods of treating a pathological condition using the same. Treatment of human cells with the new inhibitors of the present invention show a unique pattern of hyperacetylated proteins compared with the broad spectrum HDAC inhibitor TSA.
